Where Will Recursion Pharmaceuticals Be in 5 Years?

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company ...

Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?

In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment ...

Is this the end of unconscious consumerism and will AI proxies rewrite advertising?

MIT projects that by 2030, almost half of all consumer decision-making will be AI-driven. At The Drum Live, futurist Danielle ...

Hims & Hers: Navigating GLP Controversy With Aplomb, But Risks Warrant Hold Rating

Get the latest analysis on Hims & Hers Health, Inc. stock with valuation insights, business risks, and forecasts. Click here ...